Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to $42.1 million.

  • Day One Biopharmaceuticals' Change in Accured Expenses rose 107.86% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 24.21%. This contributed to the annual value of $42.1 million for FY2024, which is 298.16% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Change in Accured Expenses stood at $42.1 million for FY2024, which was up 298.16% from $10.6 million recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Change in Accured Expenses high stood at $42.1 million for FY2024, and its period low was $1.1 million during FY2020.
  • Over the past 3 years, Day One Biopharmaceuticals' median Change in Accured Expenses value was $10.6 million (recorded in 2023), while the average stood at $20.6 million.
  • Data for Day One Biopharmaceuticals' Change in Accured Expenses shows a peak YoY surged of 353.77% (in 2021) over the last 5 years.
  • Over the past 5 years, Day One Biopharmaceuticals' Change in Accured Expenses (Yearly) stood at $1.1 million in 2020, then skyrocketed by 353.77% to $5.1 million in 2021, then spiked by 80.70% to $9.2 million in 2022, then increased by 14.42% to $10.6 million in 2023, then surged by 298.16% to $42.1 million in 2024.